StockWatch
·
Biotechnology: Pharmaceutical Preparations
Quarterly ResultNov 13, 2026, 08:41 AM

MetaVia Inc. Q3 2026 Net Loss Widens to $4.62M; Assets Decline

AI Summary

MetaVia Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026. The company reported an increased net loss for both the third quarter and the first nine months of 2026 compared to the prior year. Total assets decreased, while total liabilities increased. Cash and cash equivalents also saw a reduction. Operating expenses, particularly in research and development, rose, and clinical trial accrued liabilities significantly increased, reflecting ongoing clinical trial activities.

Key Highlights

  • MetaVia Inc. reported a net loss of $4.62 million for Q3 2026, compared to $3.38 million in Q3 2025.
  • Nine-month net loss for 2026 was $13.76 million, an increase from $11.04 million in the same period of 2025.
  • Total assets decreased to $9.55 million as of September 30, 2026, from $11.12 million as of December 31, 2025.
  • Total liabilities increased to $7.14 million as of September 30, 2026, from $5.79 million as of December 31, 2025.
  • Cash and cash equivalents decreased to $8.78 million as of September 30, 2026, from $10.28 million as of December 31, 2025.
  • Research and development expenses increased to $2.59 million in Q3 2026 from $1.91 million in Q3 2025.
  • Clinical trial accrued liabilities increased significantly to $1.58 million as of September 30, 2026, from $0.08 million as of December 31, 2025.